{"id":1599,"date":"2023-06-25T17:27:16","date_gmt":"2023-06-25T17:27:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/abciximab\/"},"modified":"2023-06-25T19:57:42","modified_gmt":"2023-06-25T19:57:42","slug":"abciximab","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/abciximab\/","title":{"rendered":"Abciximab"},"content":{"rendered":"

<\/p>\n

Abciximab<\/h1>\n

CLINICAL USE<\/h3>\n

Antiplatelet agent:<\/p>\n

  • Prevention of ischaemic cardiac<\/li>\n
  • complications in patients undergoing percutaneous coronary intervention<\/li>\n
  • Short-term prevention of myocardial infarction in patients with unstable angina not responding to treatment or awaiting percutaneous coronary intervention
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    IV bolus: 250 mcg\/kg then by infusion at 0.125 mcg\/kg\/minute for 12 hours after intervention (maximum 10 mcg\/minute)<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :47 455.4<\/li>\n
  • %Protein binding                           :Binds to platelets<\/li>\n
  • %Excreted unchanged in urine     : Minimal (catabolised like other proteins)<\/li>\n
  • Volume of distribution (L\/kg)       :0.1181<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :<10 minutes\/unchanged
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function. Use with caution
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :Unlikely to be dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsHeparin, anticoagulants, antiplatelets and thrombolytics: increased risk of bleeding<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    IV bolus,<\/p>\n

    IV infusion<\/h4>\n

    Rate of Administration<\/h4>\n

    Bolus: 1 minute Infusion: 0.125 mcg\/kg\/minute (maximum 10 mcg\/minute)<\/p>\n

    Comments<\/h4>\n

    Dilute in sodium chloride 0.9% or glucose 5%Give via a non-pyrogenic low-protein- binding 0.2, 0.22 or 5 micron filter<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Increased risk of bleeding in CKD 5, benefits of abciximab treatment may be reduced<\/li>\n
  • In the UK the licence says avoid in haemodialysis patients due to increased risk of bleeding (as on heparin for dialysis) but it is used in normal doses in the USA<\/li>\n
  • Antibodies to abciximab develop 2\u20134 weeks post dose in 5.8% of patients so monitor for hypersensitivity reactions if re-administered<\/li>\n
  • Abciximab remains in the body for at least 15 days, bound to platelets<\/li>\n
  • Once infusion is stopped, the concentration of abciximab falls rapidly for 6 hours then decreases at a slower rate<\/li>\n","protected":false},"excerpt":{"rendered":"

    Abciximab CLINICAL USE Antiplatelet agent: Prevention of ischaemic cardiac complications<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1599","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1599"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1599\/revisions"}],"predecessor-version":[{"id":2916,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1599\/revisions\/2916"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}